EN

ENZYCHEM LIFESCIENCES CORPORATION

Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.

183490 | KO

Overview

Corporate Details

ISIN(s):
KR7183490002
LEI:
Country:
South Korea
Address:
충청북도 제천시 바이오밸리로 59, 제천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Enzychem Lifesciences Corporation is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for inflammatory diseases, oncology, and severe respiratory conditions. The company's primary focus is its lead candidate, EC-18 (Mosedipimod), an oral immunomodulator designed to target fundamental inflammation pathways. Its development pipeline addresses significant unmet medical needs, including chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), and acute radiation syndrome (ARS). In addition to its research and development in new drugs, the company also develops and manufactures Active Pharmaceutical Ingredients (APIs).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-06-10 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 21.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 93.4 KB
2025-04-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.9 KB
2025-03-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.3 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.5 MB
2025-03-12 00:00
Major Shareholding Notification
신탁계약에의한취득상황보고서
Korean 49.5 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 264.6 KB
2025-03-07 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 216.5 KB
2025-03-06 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.8 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.3 KB

Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden
ORX
ORGANIGRAM GLOBAL INC. Logo
Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.
United States of America
OGI
Organon & Co. Logo
A global healthcare company focused on women's health, biosimilars, and established brands worldwide.
United States of America
OGN
Oric Pharmaceuticals, Inc. Logo
Developing therapies to overcome resistance in lung and prostate cancer.
United States of America
ORIC
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland
ORNAV
Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.